2008-10-13 18:25:03 -

www.cordis.com - Cordis Corporation, a leader in transforming cardiovascular care, announced three new senior-level appointments. Carl J. St. Bernard has been named Vice President, U.S. Sales and Marketing; Paul I. Chang, M.D., has been named Vice President, Worldwide Clinical Research and Operations; and Ryan H. Saadi, M.D., M.P.H., has been named Vice President, Health Economics and Reimbursement.

"Cordis continues to attract top talent both from within Johnson & Johnson and from across the healthcare industry," said Seth Fischer, Worldwide Franchise Chairman, Cordis Corporation. "I'm confident that these three outstanding leaders will strengthen Cordis and our ability to serve customers in the rapidly changing cardiovascular marketplace."

Carl J. St. Bernard joins Cordis after serving as General Manager of the Magnetic Resonance Imaging (MRI) in the Healthcare Division at General Electric (GE), where he was instrumental in driving revenue, margin, and market share growth. His many notable accomplishments in 12 years at GE include sales performance, which placed him in the top ten of all U.S. territories and awarded him the prestigious GE "Icon" award in 2004 for sales and marketing excellence. St. Bernard will become a member of the Global Management Board (GMB) at Cordis and also will chair the U.S. Operating Board.

Paul I. Chang, M.D., who is succeeding Dr. Dennis Donohoe, who retired in August, will become a key member of the research and development leadership team and will be responsible for clinical development strategy, clinical trial execution, and the Program Management Office (PMO). Chang joined Johnson & Johnson Pharmaceutical Research and Development (J&J PRD) in 2006 as Therapeutic Area Head of Cardiovascular and transitioned to head of Internal Medicine, J&J PRD late last year. Prior to Johnson & Johnson, Chang was chief medical officer and vice president, Regulatory Affairs and Clinical Development at Tengion, Inc.

As vice president of Health Economics and Reimbursement, Ryan H. Saadi will play a critical role in Cordis' future global growth, especially as the healthcare and medical device industry changes. Saadi joins Cordis from Genzyme Corporation where he was vice president, Global Health Outcomes and Strategic Pricing, and supervised U.S. and European-based health economics and outcomes research, pricing and reimbursement teams. Prior to Genzyme Corporation, Saadi was senior director of Oncology, Bone and Arthritis, Global Health Outcomes and Market Access at Sanofi Aventis Pharmaceuticals.

About Cordis Corporation

Cordis Corporation, a Johnson & Johnson company (NYSE:JNJ), is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at www.cordis.com.

Cordis Corporation, Warren
Carol Goodrich, 908-412-7332, 973-615-4057(Mobile)